Survanta 1 ml Sterile Dispersion
PDF Leaflet Revision Date: 21 April 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment and prevention of neonatal respiratory distress syndrome (RDS).
Dosage (summary)
100 mg phospholipid/kg body weight, max 4 ml/kg; up to 4 doses within 48 hours.
Onset of Action / Duration
Onset: minutes, Duration: 72 hours
Key Drug Interactions
- Catecholamines
- Indomethacin
- Tolazoline
- Pancuronium
- Phenobarbital
- Opiates
- Antibiotics
- Parenteral nutrients
Common side effects
- Intracranial haemorrhage
- Pulmonary haemorrhage
- Blockage of endotracheal tube
Counselling Points
- Warm vial before use
- Administer intratracheally
- Monitor oxygenation closely
Serious warnings
- Monitor for hyperoxia
- Transient bradycardia and oxygen desaturation may occur
Important Disclaimer
The Survanta 1 ml Sterile Dispersion professional information leaflet below is the property of AbbVie and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
